A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18 to 65 years of age inclusive
Chronic hepatitis C, genotype 1 or 4
Cohort 1: Treatment-naïve for hepatitis C
Cohort 2: Prior null responder to treatment with approved doses of pegylated interferon plus ribavirin
Liver biopsy confirming cirrhosis
Compensated cirrhosis (Child-Pugh A)
You may not be if
Pregnant or lactating women or male partners of women who are pregnant
History or presence of decompensated liver disease (ascites, hepatic encephalopathy, hepatocellular carcinoma, or bleeding esophageal varices)
Cohort 2: Patients who discontinued previous pegylated interferon plus ribavirin treatment due to reasons other than null response
History of clinically significant cardiovascular or cerebrovascular disease
Clareo Health | A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
